Literature DB >> 15247596

Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies.

Mylena Lima1, Regina Célia De Menezes Succi, Amélia M Nunes Dos Santos, Lily Yin Weckx, Maria Isabel De Moraes-Pinto.   

Abstract

BACKGROUND: HIV infection can have important although sometimes unexpected consequences, such as contributing to enlargement of the pool of rubella-susceptible children.
METHODS: At the Federal University of São Paulo, Brazil, we assessed response to rubella immunization at 15 months of age in 15 human immunodeficiency virus type 1 (HIV)-infected children, 20 seroreverted children (SR) and 18 healthy control children born to HIV-seronegative mothers (CON). Blood samples were collected before and 3 months after vaccination. All HIV-infected children had started highly active antiretroviral therapy during their first 6 months of life. Serum samples were tested with a rubella IgG enzyme-linked immunosorbent assay kit.
RESULTS: HIV children in immunologic categories 2/3 had lower rubella antibody titers (geometric mean, 33 IU/mL) than those from CON (125 IU/mL) and SR group (236 IU/mL) (Tukey, P = 0.01). Antibody values after vaccination were positively associated with CD4 T cell numbers and negatively associated with HIV viral load assessed immediately before vaccination. The percentage of children with protective antibodies after vaccination (above 10.0 IU/mL) was also significantly different among groups (Fisher's exact test, P = 0.013): CON, 94%; SR, 100%; HIV category 1, 100%; HIV category 2/3, 62%.
CONCLUSIONS: HIV-infected children with a preserved immune system at measles-mumps-rubella immunization can have a good response to rubella vaccine. In contrast, those in more advanced categories for HIV infection respond poorly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247596     DOI: 10.1097/01.inf.0000128780.79145.5c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.

Authors:  George K Siberry; Kunjal Patel; William J Bellini; Brad Karalius; Murli U Purswani; Sandra K Burchett; William A Meyer; Sun Bae Sowers; Angela Ellis; Russell B Van Dyke
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

Review 2.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

3.  Immunity After Childhood Vaccinations in Perinatally HIV-exposed Children With and Without HIV Infection in Latin America.

Authors:  Regina C M Succi; Margot R Krauss; D Robert Harris; Daisy M Machado; Maria I de Moraes-Pinto; Marisa M Mussi-Pinhata; Noris Pavia Ruz; Russell B Pierre; Lenka A Kolevic Roca; Esaú Joao; Irene Foradori; Marcelo C Scotta; Rohan Hazra; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2018-04       Impact factor: 2.129

4.  Updated Recommendations for the Use of Varicella and MMR Vaccines In HIV-Infected Individuals: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-16

5.  Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART).

Authors:  Natascha Ching; Jaime G Deville; Karin A Nielsen; Bonnie Ank; Lian S Wei; Myung Shin Sim; Steven M Wolinsky; Yvonne J Bryson
Journal:  Eur J Pediatr       Date:  2006-07-26       Impact factor: 3.183

6.  Vaccination in patients with HIV infection.

Authors:  Todd D Gleeson; Mark R Wallace; Sybil A Tasker
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.663

7.  Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.

Authors:  Romanee Chaiwarith; Jutarat Praparattanapan; Khanuengnit Nuket; Wilai Kotarathitithum; Khuanchai Supparatpinyo
Journal:  BMC Infect Dis       Date:  2016-04-30       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.